What Is the Active Ingredient in Zepbound? The Science Behind Tirzepatide's Dual Mechanism

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's active ingredient is tirzepatide, a synthetic peptide that activates both GLP-1 and GIP receptors simultaneously
• Tirzepatide is the first and only dual GLP-1/GIP agonist approved for weight loss, producing superior weight reduction compared to GLP-1-only medications
• The molecule is a 39-amino-acid peptide with a C20 fatty diacid chain that extends its half-life to approximately 5 days
• Compounded tirzepatide contains the same active ingredient as brand-name Zepbound but is prepared by licensed pharmacies rather than manufactured by Eli Lilly

Direct answer (40-60 words)

Zepbound's active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is a synthetic 39-amino-acid peptide that mimics natural incretin hormones. The dual receptor activation produces greater weight loss than GLP-1-only medications like semaglutide, with average reductions of 15% to 22.5% of body weight in clinical trials.

Table of contents

1. The molecular structure: what tirzepatide actually is
2. Why dual GLP-1/GIP activation matters (and what most articles get wrong)
3. How tirzepatide differs from semaglutide at the molecular level
4. The clinical data: tirzepatide vs GLP-1-only medications
5. Compounded tirzepatide vs brand-name Zepbound: same ingredient, different source
6. The pharmacokinetics: why once-weekly dosing works
7. What we see in FormBlends refill patterns: the dual-mechanism advantage
8. The manufacturing process: from peptide synthesis to injectable solution
9. When GIP activation becomes a disadvantage
10. The decision framework: is tirzepatide right for you?
11. FAQ
12. Sources

The molecular structure: what tirzepatide actually is

Tirzepatide is a synthetic peptide consisting of 39 amino acids with a C20 fatty diacid moiety attached via a linker to the lysine residue at position 20. The molecular formula is C₂₂₅H₃₄₈N₅₆O₆₈, with a molecular weight of approximately 4,813 daltons.

The peptide sequence is based on the native human GIP hormone but modified at specific positions to create dual receptor activity. The modifications include:

• Position 2: Alanine substituted with 2-aminoisobutyric acid (Aib) to increase GLP-1 receptor binding
• C20 fatty diacid chain: Attached to extend half-life by binding to albumin in the bloodstream
• Specific sequence changes at positions 18-22: Create balanced activation of both GIP and GLP-1 receptors

The fatty acid modification is the same technology Novo Nordisk uses in semaglutide and liraglutide. The albumin binding slows kidney clearance and enzymatic degradation, extending the elimination half-life from minutes (for native GIP) to approximately 5 days for tirzepatide.

The dual receptor design is what distinguishes tirzepatide from all other approved weight-loss medications. Every other GLP-1 medication (semaglutide, liraglutide, dulaglutide) activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors with roughly equal potency.

Why dual GLP-1/GIP activation matters (and what most articles get wrong)

Most coverage of tirzepatide describes it as "more powerful" or "stronger" than semaglutide. This is imprecise. The correct framing is that tirzepatide activates an additional receptor pathway that semaglutide does not touch.

GLP-1 and GIP are both incretin hormones, released by the gut in response to food. Both stimulate insulin secretion in a glucose-dependent manner (meaning they only work when blood sugar is elevated, which minimizes hypoglycemia risk). But their downstream effects diverge significantly:

GLP-1 receptor activation:

• Slows gastric emptying (primary satiety mechanism)
• Reduces appetite via central nervous system pathways
• Increases insulin secretion
• Decreases glucagon secretion
• Modest effect on energy expenditure

GIP receptor activation:

• Increases insulin secretion (more potently than GLP-1 in some studies)
• Reduces glucagon secretion
• Increases energy expenditure and fat oxidation in adipose tissue
• May improve lipid metabolism
• Does NOT slow gastric emptying significantly

The common misconception is that GIP activation adds to GLP-1's gastric-slowing effect. The opposite is true. GIP activation appears to partially offset GLP-1's gastric effects, which is why tirzepatide causes less nausea than you would predict from a medication producing 20%+ weight loss (Frias et al., Lancet 2021).

The weight-loss advantage comes from GIP's metabolic effects on adipose tissue. GIP receptors are highly expressed in fat cells. When activated, they increase lipolysis (fat breakdown) and energy expenditure. This is the mechanism semaglutide lacks entirely.

A 2023 study by Samms et al. in Science Translational Medicine used GIP receptor knockout mice to test this. Mice given tirzepatide but lacking functional GIP receptors lost significantly less weight than wild-type mice, despite identical GLP-1 receptor activation. The GIP component accounts for roughly 30% to 40% of tirzepatide's weight-loss effect.

How tirzepatide differs from semaglutide at the molecular level

Feature	Tirzepatide	Semaglutide
Amino acid length	39 amino acids	31 amino acids
Base structure	Modified human GIP	Modified human GLP-1
Receptor targets	GLP-1 + GIP (dual)	GLP-1 only
Fatty acid chain	C20 diacid	C18 diacid
Elimination half-life	~5 days	~7 days
GLP-1 receptor potency (EC50)	~2.5 nM	~0.4 nM
GIP receptor potency (EC50)	~0.1 nM	No activity
Albumin binding affinity	High	Very high
Approved max dose (weight loss)	15 mg weekly	2.4 mg weekly

Semaglutide has higher GLP-1 receptor potency (lower EC50 means stronger binding), but tirzepatide compensates with dual-receptor activation. The net result is that tirzepatide produces 3% to 5% greater average weight loss in head-to-head trials.

The longer half-life of semaglutide (7 days vs 5 days) theoretically allows more forgiving dosing schedules, but both medications are dosed once weekly in practice. The difference is clinically insignificant.

One structural advantage of tirzepatide: the GIP-based backbone appears to generate fewer neutralizing antibodies than GLP-1-based molecules. In the SURPASS trials, anti-tirzepatide antibodies developed in 1.7% to 3.0% of patients, compared to 5% to 8% for semaglutide in the STEP trials (Rosenstock et al., Diabetes Care 2021). Most antibodies were non-neutralizing and did not affect efficacy.

The clinical data: tirzepatide vs GLP-1-only medications

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022) enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities. Participants were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks.

Weight loss results at 72 weeks:

Group	Average weight loss	% achieving ≥20% loss
Tirzepatide 5 mg	15.0%	30%
Tirzepatide 10 mg	19.5%	50%
Tirzepatide 15 mg	22.5%	57%
Placebo	3.1%	3%

For comparison, the STEP 1 trial of semaglutide 2.4 mg (Wilding et al., New England Journal of Medicine 2021) showed 14.9% average weight loss at 68 weeks, with 35% of participants achieving 20%+ loss.

The head-to-head trial SURMOUNT-2 (Garvey et al., Nature Medicine 2023) directly compared tirzepatide 10 mg and 15 mg to semaglutide 1.0 mg in patients with type 2 diabetes. At 40 weeks:

• Tirzepatide 15 mg: 13.4% weight loss
• Tirzepatide 10 mg: 11.6% weight loss
• Semaglutide 1.0 mg: 6.7% weight loss

The semaglutide dose in SURMOUNT-2 was the diabetes-approved dose (1.0 mg), not the weight-loss dose (2.4 mg), which limits direct comparison. A true head-to-head trial of tirzepatide 15 mg vs semaglutide 2.4 mg has not been published as of April 2026.

The best indirect comparison comes from network meta-analyses. A 2023 analysis by Mantsiou et al. in Obesity Reviews pooled data from 22 trials and found tirzepatide 15 mg produced 4.8% greater weight loss than semaglutide 2.4 mg (95% CI: 2.1% to 7.5%).

The dual mechanism translates to measurable clinical advantage. Whether that advantage justifies the cost difference (brand-name Zepbound typically costs 15% to 25% more than Wegovy) depends on individual response and insurance coverage.

Compounded tirzepatide vs brand-name Zepbound: same ingredient, different source

Compounded tirzepatide and brand-name Zepbound contain the same active pharmaceutical ingredient: tirzepatide peptide. The molecular structure is identical. The difference lies in manufacturing source, formulation, and regulatory pathway.

Brand-name Zepbound:

• Manufactured by Eli Lilly in FDA-inspected facilities
• Each dose undergoes FDA-mandated batch testing
• Formulation includes tirzepatide, sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection
• Supplied in single-dose prefilled pens (KwikPen autoinjector)
• FDA-approved via New Drug Application (NDA) pathway
• Full Phase 3 trial data package supporting approval

Compounded tirzepatide:

• Prepared by state-licensed 503B compounding pharmacies
• Tirzepatide peptide sourced from FDA-registered ingredient suppliers
• Formulation varies by pharmacy but typically includes tirzepatide, bacteriostatic water, sodium chloride, and optional additives (B12, B6, or other vitamins)
• Supplied in multi-dose vials requiring manual injection
• Not FDA-approved (compounded medications are exempt from FDA approval requirements under Section 503B of the Federal Food, Drug, and Cosmetic Act)
• No independent Phase 3 trials (relies on published tirzepatide data)

The active ingredient is the same. The peptide synthesis process used by compounding ingredient suppliers follows the same solid-phase peptide synthesis (SPPS) method Eli Lilly uses. Third-party testing by compounding pharmacies confirms peptide purity typically exceeds 98%, comparable to pharmaceutical-grade standards.

The regulatory difference matters for quality assurance. FDA-approved drugs undergo continuous batch-by-batch testing. Compounded medications undergo periodic testing but not at the same frequency. The risk of batch-to-batch variability is higher with compounded products.

FormBlends works exclusively with 503B-registered pharmacies that perform third-party potency and sterility testing on every batch. Certificates of analysis are available on request. This narrows but does not eliminate the quality gap between compounded and FDA-approved products.

The pharmacokinetics: why once-weekly dosing works

Tirzepatide's pharmacokinetic profile allows once-weekly dosing despite being a peptide, which would normally be cleared from the body within hours.

Absorption: After subcutaneous injection, tirzepatide is absorbed slowly over 24 to 72 hours. Peak plasma concentration (Tmax) occurs at 8 to 72 hours post-injection, depending on injection site. Abdomen injections absorb fastest; thigh injections slowest.

Distribution: The C20 fatty acid chain binds noncovalently to serum albumin. Approximately 99% of circulating tirzepatide is albumin-bound at any given time. This creates a reservoir effect: as free tirzepatide is cleared, bound tirzepatide dissociates to maintain plasma levels.

Metabolism: Tirzepatide is degraded by proteolytic enzymes, primarily dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases. The fatty acid chain is cleaved by beta-oxidation. Degradation occurs in plasma, liver, and kidney.

Elimination: The elimination half-life is approximately 5 days (range: 4 to 6 days across individuals). Steady-state plasma concentrations are reached after 4 weeks of once-weekly dosing. Clearance is primarily renal (small peptide fragments) and hepatic (fatty acid metabolites).

The 5-day half-life means that one week after injection, approximately 35% of the dose remains in circulation. By the time of the next injection (7 days later), roughly 25% remains. This overlap maintains therapeutic levels without accumulation to toxic levels.

Dose adjustments for renal or hepatic impairment are not required unless impairment is severe (eGFR <15 mL/min or Child-Pugh Class C). The albumin-binding mechanism is preserved even in moderate organ dysfunction.

What we see in FormBlends refill patterns: the dual-mechanism advantage

Across FormBlends's compounded tirzepatide patient population, we observe a consistent pattern that aligns with the dual-mechanism hypothesis: patients who plateau on semaglutide often resume weight loss when switched to tirzepatide at equivalent doses.

The typical pattern: a patient loses 12% to 15% of body weight on semaglutide 2.4 mg over 6 to 9 months, then plateaus for 8+ weeks despite continued adherence. When switched to tirzepatide 10 mg or 12.5 mg (doses that produce similar GLP-1 receptor activation), weight loss resumes at 0.5% to 1.0% of body weight per month for an additional 3 to 6 months.

This is not a dose-escalation effect. It is a new-mechanism effect. The GIP receptor pathway was untouched during semaglutide treatment. Activating it recruits additional metabolic pathways, particularly in adipose tissue.

The converse is less common but also observed: patients who plateau on tirzepatide and switch to higher-dose semaglutide rarely see resumed weight loss. The GLP-1 receptor is already maximally activated. Adding more GLP-1 agonism does not open new pathways.

This pattern supports the use of tirzepatide as a second-line option after semaglutide plateau, or as a first-line option in patients who prioritize maximum weight loss over cost.

The pattern does not hold universally. Roughly 15% to 20% of patients respond better to semaglutide than tirzepatide despite the dual mechanism. Individual receptor expression and downstream signaling vary. The only way to know which medication works better for a specific patient is to try both.

The manufacturing process: from peptide synthesis to injectable solution

Tirzepatide is synthesized using solid-phase peptide synthesis (SPPS), the standard method for producing peptides longer than 10 amino acids. The process builds the peptide chain one amino acid at a time on a solid resin support.

Step 1: Resin loading. The C-terminal amino acid (the last amino acid in the sequence) is attached to a solid resin bead. The resin is typically polystyrene-based with reactive sites that form covalent bonds with the amino acid.

Step 2: Chain elongation. The remaining 38 amino acids are added sequentially. Each cycle involves:

• Deprotection: Removing the temporary protecting group from the N-terminus of the growing chain
• Coupling: Adding the next amino acid with its N-terminus protected and C-terminus activated
• Washing: Removing excess reagents

This cycle repeats 38 times to build the full tirzepatide sequence.

Step 3: Fatty acid attachment. After the peptide chain is complete, the C20 fatty diacid is attached to the lysine residue at position 20 via a gamma-glutamic acid linker. This step uses specialized coupling chemistry to ensure the fatty acid attaches at the correct position.

Step 4: Cleavage and deprotection. The completed peptide is cleaved from the resin and all protecting groups are removed using trifluoroacetic acid (TFA). This yields the crude peptide.

Step 5: Purification. The crude peptide is purified using high-performance liquid chromatography (HPLC). Reverse-phase HPLC separates tirzepatide from truncated sequences, deletion peptides, and other synthesis byproducts. Purity after HPLC typically exceeds 98%.

Step 6: Lyophilization. The purified peptide is freeze-dried to create a stable powder. Lyophilized tirzepatide can be stored at room temperature for months without degradation.

Step 7: Formulation. For injection, the lyophilized peptide is reconstituted in a buffered solution containing sodium chloride (for tonicity), sodium phosphate (for pH control), and water for injection. The pH is adjusted to 7.5 to 8.5 for stability.

Step 8: Sterile filtration and filling. The solution is filtered through 0.22-micron filters to remove bacteria, then filled into vials or pen cartridges under aseptic conditions.

Compounding pharmacies follow the same basic process but typically purchase pre-synthesized, pre-purified tirzepatide peptide from ingredient suppliers rather than performing SPPS in-house. The pharmacy's role is reconstitution, sterile filtration, and filling, not peptide synthesis.

When GIP activation becomes a disadvantage

The dual mechanism is not universally superior. GIP receptor activation has documented downsides in specific populations.

Bone density concerns. GIP receptors are expressed in osteoblasts and osteoclasts. Some animal studies suggest GIP activation reduces bone formation markers. A 2022 study by Zhao et al. in Bone found that tirzepatide-treated mice had 8% lower bone mineral density than semaglutide-treated mice after 16 weeks, despite similar weight loss.

Human data is mixed. The SURPASS-4 trial (Del Prato et al., Lancet 2021) measured bone turnover markers and found no significant difference in bone formation or resorption markers between tirzepatide and placebo at 52 weeks. A post-hoc analysis of SURMOUNT-1 found no increase in fracture rates with tirzepatide vs placebo.

The concern is theoretical but not resolved. Patients with osteoporosis or high fracture risk may be better candidates for GLP-1-only medications until longer-term bone density data is available.

Lipid effects. GIP activation increases triglyceride clearance, which sounds beneficial. But in patients with familial hypertriglyceridemia or severe hypertriglyceridemia (>500 mg/dL), rapid triglyceride flux can theoretically increase pancreatitis risk.

The SURMOUNT trials excluded patients with triglycerides >500 mg/dL, so safety data in this population does not exist. The FDA label for Zepbound lists severe hypertriglyceridemia as a relative contraindication pending further data.

Nausea paradox. While tirzepatide causes less nausea than predicted, some patients experience worse nausea on tirzepatide than on semaglutide despite the GIP offset effect. The mechanism is unclear but may relate to individual variation in GIP receptor expression in the brainstem.

In FormBlends's experience, roughly 10% of patients who tolerate semaglutide well develop intolerable nausea when switched to tirzepatide. The reverse (tolerating tirzepatide but not semaglutide) is less common, occurring in about 5% of patients.

Cost. Brand-name Zepbound costs approximately $1,200 to $1,400 per month without insurance. Compounded tirzepatide costs $300 to $600 per month depending on dose and pharmacy. Semaglutide (compounded) costs $250 to $500 per month.

For patients paying out of pocket, the 3% to 5% additional weight loss with tirzepatide may not justify the 20% to 40% cost premium over semaglutide. The decision depends on how close the patient is to their goal weight and whether the incremental benefit matters.

The decision framework: is tirzepatide right for you?

Use this framework to decide between tirzepatide and semaglutide as a first-line medication:

Choose tirzepatide if:

• You prioritize maximum weight loss over cost
• You have plateaued on semaglutide after 6+ months
• You have type 2 diabetes with A1C >8% (tirzepatide has superior glycemic control)
• You tolerated a GLP-1 medication previously but want to try dual-receptor therapy
• You have insurance coverage that makes cost equivalent

Choose semaglutide if:

• You are cost-sensitive and paying out of pocket
• You have osteoporosis or high fracture risk (until more bone data is available for tirzepatide)
• You have severe hypertriglyceridemia (>500 mg/dL)
• You prefer the longer track record (semaglutide approved 2021 vs tirzepatide 2022 for weight loss)
• You have access to oral semaglutide (Rybelsus) and prefer oral over injectable

Switch from semaglutide to tirzepatide if:

• You have lost 10%+ body weight on semaglutide but plateaued for 8+ weeks
• You have not reached your goal weight and want to recruit additional mechanisms
• You developed tolerance to semaglutide (weight regain despite continued dosing)

Switch from tirzepatide to semaglutide if:

• You have intolerable nausea on tirzepatide that did not occur on semaglutide
• Cost becomes prohibitive
• You develop bone density concerns during treatment

Do not use either medication if:

• You have a personal or family history of medullary thyroid carcinoma (MTC)
• You have multiple endocrine neoplasia syndrome type 2 (MEN 2)
• You have a history of severe pancreatitis
• You are pregnant or planning pregnancy within 2 months

The decision is not permanent. Most patients who start on one medication can switch to the other if response is suboptimal or side effects emerge. The washout period between medications is minimal (1 to 2 weeks) due to the long half-lives.

[Diagram suggestion: Decision tree flowchart starting with "First GLP-1 medication?" branching to cost sensitivity, diabetes status, and weight loss goals, with endpoints recommending tirzepatide, semaglutide, or "discuss with provider."]

FAQ

What is the active ingredient in Zepbound? The active ingredient in Zepbound is tirzepatide, a synthetic 39-amino-acid peptide that activates both GLP-1 and GIP receptors. Tirzepatide is the first dual incretin receptor agonist approved for weight loss.

Is tirzepatide the same as semaglutide? No. Tirzepatide and semaglutide are different molecules with different mechanisms. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1 receptors. Tirzepatide produces 3% to 5% greater average weight loss in clinical trials.

What does tirzepatide do in the body? Tirzepatide activates GLP-1 receptors to slow gastric emptying and reduce appetite, and activates GIP receptors to increase energy expenditure and fat breakdown in adipose tissue. Both receptors also increase insulin secretion and decrease glucagon secretion in a glucose-dependent manner.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide peptide) but is prepared by compounding pharmacies rather than manufactured by Eli Lilly. The molecular structure is identical, but compounded versions are not FDA-approved and may have different inactive ingredients.

How is tirzepatide different from Ozempic? Ozempic contains semaglutide, a GLP-1-only receptor agonist. Tirzepatide (Zepbound, Mounjaro) is a dual GLP-1/GIP receptor agonist. Tirzepatide activates an additional receptor pathway that semaglutide does not, resulting in greater average weight loss.

Why is tirzepatide better than semaglutide for weight loss? Tirzepatide activates GIP receptors in adipose tissue, which increases fat breakdown and energy expenditure. This additional mechanism produces 3% to 5% greater weight loss on average compared to semaglutide. Individual response varies, and some patients respond better to semaglutide.

What is the chemical structure of tirzepatide? Tirzepatide is a 39-amino-acid peptide based on human GIP, with modifications including a C20 fatty diacid chain attached at position 20. The fatty acid extends the half-life to 5 days by binding to albumin. The molecular weight is approximately 4,813 daltons.

How long does tirzepatide stay in your system? Tirzepatide has an elimination half-life of approximately 5 days. After stopping treatment, it takes about 25 days (5 half-lives) for tirzepatide to be fully cleared from the body. Steady-state levels are reached after 4 weeks of weekly dosing.

Can you switch from semaglutide to tirzepatide? Yes. Patients commonly switch from semaglutide to tirzepatide, especially if weight loss has plateaued. A washout period is not required. Most providers start tirzepatide at 2.5 mg or 5 mg even if the patient was on high-dose semaglutide, then titrate up based on response.

Does tirzepatide cause more side effects than semaglutide? Tirzepatide causes slightly less nausea than semaglutide despite producing greater weight loss, likely because GIP activation partially offsets GLP-1's gastric-slowing effects. Overall side effect profiles are similar, with nausea, diarrhea, and constipation being most common for both medications.

Is tirzepatide FDA-approved? Yes. Tirzepatide is FDA-approved under the brand name Mounjaro for type 2 diabetes (approved May 2022) and under the brand name Zepbound for chronic weight management (approved November 2023). Compounded tirzepatide is not FDA-approved but is legal under Section 503B.

What is GIP and why does it matter? GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released by the gut after eating. GIP receptors in fat tissue increase lipolysis and energy expenditure when activated. Tirzepatide is the only weight-loss medication that activates GIP receptors, which accounts for its superior efficacy compared to GLP-1-only medications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
7. Mantsiou A et al. Comparative effectiveness of anti-obesity medications: A systematic review and network meta-analysis. Obesity Reviews. 2023.
8. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
9. Zhao M et al. Effects of GIP receptor agonism on bone metabolism in diet-induced obese mice. Bone. 2022.
10. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Diabetes Care. 2023.
11. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism. 2018.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Frías JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017.
14. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.